Recurrent PIK3CA-E545K mutation promotes cervical cancer growth and invasion via AKT/mTOR signaling.
Summary
This study investigated the functional impact of recurrent mutations in cervical cancer. Using whole-exome sequencing, cell models, and in vivo experiments, researchers identified the PIK3CA-E545K mutation as frequently occurring. This specific mutation was shown to enhance tumor cell proliferation and invasion while suppressing apoptosis. These effects are mediated by sustained activation of the AKT/mTOR signaling pathway. The findings suggest that targeting the PI3K/AKT/mTOR axis could represent a promising therapeutic strategy for this cancer.
Analysis
BIOMOL: This study identified the recurrent PIK3CA-E545K mutation as a key driver of cervical cancer growth and invasion, acting via AKT/mTOR pathway activation. The discovery was made using whole-exome sequencing on patient samples, followed by functional validation in vitro and in vivo. This represents an advance in understanding the molecular mechanisms of cervical carcinogenesis and highlights a potential biomarker. WES technology is robust for variant identification, and functional validations strengthen the biological validity of this discovery. CLINIQUE: Clinically, this research provides strong experimental support for targeting the PI3K/AKT/mTOR axis in cervical cancer, particularly in patients harboring the PIK3CA-E545K mutation. Although a preclinical study, the demonstration of a clear oncogenic role for this mutation and the identification of an activated signaling pathway justify the development or re-purposing of phase I/II clinical trials evaluating PI3K/AKT/mTOR inhibitors in these patients. PIK3CA-E545K could serve as a predictive biomarker for patient selection, with potential clinical impact in the medium term (3-5 years) if targeted therapies prove effective.